Rhabdomyosarcoma Market Research Report – Forecast to 2027

Global Rhabdomyosarcoma Research Report: By Type (Embryonal & Alveolar), by Diagnosis (X-Ray, CT scan, MRI, PET scan, Bone scan, Needle & Surgical Biopsy), and by Treatment (Surgery, Radiation Therapy, Chemotherapy, Stem Cell Therapy)—Forecast Till 2027

ID: MRFR/Pharma/5107-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The global rhabdomyosarcoma market is expected to grow significantly over the forecast period. It is estimated that the global rhabdomyosarcoma market is expected to register a CAGR ~ 4.8 % during the forecast period of 2018–2023. Rhabdomyosarcoma is a type of cancerous tumor that starts to develop in the soft tissues of the body. Cells affected by rhabdomyosarcoma can grow and spread very fast.


Numerous factors such as raising awareness of rhabdomyosarcoma and its increasing prevalence are expected to drive the growth of the market.


Moreover, favorable healthcare investments by government and the rising demand for better treatments boosts the growth of the market. However, stringent government regulation for product approval and huge costs of the treatment may hamper the market growth during the assessment period.


Segmentation


The global rhabdomyosarcoma market has been segmented into type, diagnosis, and treatment.


The market, on the basis of type, has been segmented into Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma.


The market, by diagnosis, has been segmented into Imaging Tests and Biopsy.


Imaging tests are further segmented into X-Ray, MRI scan, CT scan, PET scan, and Bone Scan.


Biopsy is further segmented into Needle Biopsy and Surgery Biopsy.


The market, by treatment, has been segmented into Surgery, Radiation Therapy, Chemotherapy and Stem Cell Therapy. Chemotherapy is expected to account for the largest market share due to its effective treatment for minimizing the risk of cancer reoccurrence and high preference among the patients. Radiation therapy is anticipated to be the fastest growing segment due to technological advancements in the segment.


The market, by region, has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rhabdomyosarcoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European rhabdomyosarcoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The rhabdomyosarcoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rhabdomyosarcoma market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly & Company, Novartis AG, Bristol Myers Squibb Company, TAIHO ONCOLOGY, INC., Oasmia, Bellicum Pharmaceuticals, Inc., CELGENE CORPORATION, Eisai Co., Ltd., MacroGenics, Inc., NantKwest., Tarveda Therapeutics., Exelixis, Inc., and Ipsen Pharma are some of the key players in the global rhabdomyosarcoma market.


Regional Market Summary


Global Rhabdomyosarcoma Market Share (%), by Region, 2017


Rhabdomyosarcoma Market Share


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the global rhabdomyosarcoma market owing to growing incidences of rhabdomyosarcoma and other soft tissue cancers. According to a report published by The American Cancer Society in July 2018, in the US records approximately 400 to 500 new cases of rhabdomyosarcoma every year. Additionally, government support in this region contributes to the growth of the market.


Europe is expected to hold the second largest position in the global rhabdomyosarcoma market. The market growth in this region is attributed to the increasing healthcare expenditure.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population suffering from rhabdomyosarcoma, market players introducing new anticancer molecules in the region and raising awareness about cancer. For instance, in February 2016, Eisai Co., Ltd. received approval for developing its anticancer agent Halaven in Japan. A drug is a treatment option for treating patients suffering from soft tissue sarcomas.


On the other hand, the Middle East & Africa has the lowest market share. Majority of the market of this region is expected to be held by the Middle East region due to rising cases of rhabdomyosarcoma.


Global Rhabdomyosarcoma Market, by Type



  • Embryonal Rhabdomyosarcoma

  • Alveolar Rhabdomyosarcoma


Global Rhabdomyosarcoma Market, by Diagnosis



  • Imaging Tests



  • X-Ray

  • CT Scan

  • MRI Scan

  • PET Scan

  • Bone Scan

  • Biopsy

  • Needle Biopsy

  • Surgical Biopsy


Global Rhabdomyosarcoma Market, by Treatment



  • Surgery

  • Radiation Therapy

  • Chemotherapy

  • Stem Cell Therapy


Global Rhabdomyosarcoma Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Pharmaceutical Companies

  • Rhabdomyosarcoma Drug Suppliers & Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Government Research Institute

  • Academic Institutes and Universities



Frequently Asked Questions (FAQ) :


Rhabdomyosarcoma Market is projected to grow at a 4.8% CAGR between 2020-2027.

The Americas is projected to command the largest share in Rhabdomyosarcoma Market.

Chemotherapy segment will dominate Rhabdomyosarcoma Market.

Increasing prevalence of rhabdomyosarcoma is boosting market growth.

Huge treatment cost may limit market growth.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Rhabdomyosarcoma Market, by Type

6.1 Introduction

6.2 Embryonal Rhabdomyosarcoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Alveolar Rhabdomyosarcoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Rhabdomyosarcoma Market, by Diagnosis

7.1 Introduction

7.2 Imaging Tests

7.2.1 X-Ray

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2 CT Scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.3 MRI Scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.4 PET Scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.5 Bone Scan

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Biopsy

7.3.1 Needle Biopsy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3.2 Surgical Biopsy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Rhabdomyosarcoma Market, by Treatment

8.1 Introduction

8.2 Surgery

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Radiation Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Chemotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Stem Cell Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Rhabdomyosarcoma Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Eli Lilly and Company

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Boehringer Ingelheim International GmbH

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Pfizer Inc.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 NOVARTIS AG

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Bristol Myers Squibb Company

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Oasmia

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Bellicum Pharmaceuticals, Inc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 CELGENE CORPORATION

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Eisai Co., Ltd.

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 MacroGenics, Inc.

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 NantKwest

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 TAIHO ONCOLOGY, INC.

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Tarveda Therapeutics

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.14 Exelixis, Inc.

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Ipsen Pharma

11.15.1 Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Rhabdomyosarcoma Industry

Chapter 13. Appendix


LIST OF TABLES

Table 1 Global Rhabdomyosarcoma Market Synopsis, 2020–2027

Table 2 Global Rhabdomyosarcoma Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Rhabdomyosarcoma Market, by Region, 2020–2027 (USD Million)

Table 4 Global Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 5 Global Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 6 Global Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 7 North America: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 8 North America: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 9 North America: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 10 US: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 11 US: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 12 US: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 13 Canada: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 14 Canada: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 15 Canada: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 16 South America: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 17 South America: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 18 South America: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 19 Europe: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 20 Europe: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 21 Europe: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 22 Western Europe: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 23 Western Europe: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 24 Western Europe: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 25 Eastern Europe: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 26 Eastern Europe: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 27 Eastern Europe: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 28 Asia-Pacific: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 29 Asia-Pacific: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 30 Asia-Pacific: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

Table 31 Middle East & Africa: Rhabdomyosarcoma Market, by Type, 2020–2027 (USD Million)

Table 32 Middle East & Africa: Rhabdomyosarcoma Market, by Diagnosis, 2020–2027 (USD Million)

Table 33 Middle East & Africa: Rhabdomyosarcoma Market, by Treatment, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Rhabdomyosarcoma Market

Figure 3 Segmentation Market Dynamics for Global Rhabdomyosarcoma Market

Figure 4 Global Rhabdomyosarcoma Market Share, by Type, 2020

Figure 5 Global Rhabdomyosarcoma Market Share, by Diagnosis, 2020

Figure 6 Global Rhabdomyosarcoma Market Share, by Treatment, 2020

Figure 7 Global Rhabdomyosarcoma Market Share, by Region, 2020

Figure 8 North America: Rhabdomyosarcoma Market Share, by Country, 2020

Figure 9 Europe: Rhabdomyosarcoma Market Share, by Country, 2020

Figure 10 Asia-Pacific: Rhabdomyosarcoma Market Share, by Country, 2020

Figure 11 Middle East & Africa: Rhabdomyosarcoma Market Share, by Country, 2020

Figure 12 Global Rhabdomyosarcoma Market: Company Share Analysis, 2020 (%)

Figure 13 Eli Lilly and Company: Key Financials

Figure 14 Eli Lilly and Company: Segmental Revenue

Figure 15 Eli Lilly and Company: Geographical Revenue

Figure 16 Boehringer Ingelheim International GmbH: Key Financials

Figure 17 Boehringer Ingelheim International GmbH: Segmental Revenue

Figure 18 Boehringer Ingelheim International GmbH: Geographical Revenue

Figure 19 Pfizer Inc: Key Financials

Figure 20 Pfizer Inc: Segmental Revenue

Figure 21 Pfizer Inc: Geographical Revenue

Figure 22 NOVARTIS AG : Key Financials

Figure 23 NOVARTIS AG: Segmental Revenue

Figure 24 NOVARTIS AG : Geographical Revenue

Figure 25 Bristol Myers Squibb Company: Key Financials

Figure 26 Bristol Myers Squibb Company: Segmental Revenue

Figure 27 Bristol Myers Squibb Company. Geographical Revenue

Figure 28 Oasmia: Key Financials

Figure 29 Oasmia: Segmental Revenue

Figure 30 Oasmia: Geographical Revenue

Figure 31 Bellicum Pharmaceuticals, Inc.: Key Financials

Figure 32 Bellicum Pharmaceuticals, Inc.: Segmental Revenue

Figure 33 Bellicum Pharmaceuticals, Inc.: Geographical Revenue

Figure 34 CELGENE CORPORATION: Key Financials

Figure 35 CELGENE CORPORATION: Segmental Revenue

Figure 36 CELGENE CORPORATION: Geographical Revenue

Figure 37 Eisai Co., Ltd.: Key Financials

Figure 38 Eisai Co., Ltd.: Segmental Revenue

Figure 39 Eisai Co., Ltd.: Geographical Revenue

Figure 40 MacroGenics, Inc.: Key Financials

Figure 41 MacroGenics, Inc.: Segmental Revenue

Figure 42 MacroGenics, Inc.: Geographical Revenue

Figure 43 NantKwest: Key Financials

Figure 44 NantKwest: Segmental Revenue

Figure 45 NantKwest.: Geographical Revenue

Figure 46 TAIHO ONCOLOGY, INC.: Key Financials

Figure 47 TAIHO ONCOLOGY, INC.: Segmental Revenue

Figure 48 TAIHO ONCOLOGY, INC.: Geographical Revenue

Figure 49 Tarveda Therapeutics.: Key Financials

Figure 50 Tarveda Therapeutics.: Segmental Revenue

Figure 51 Tarveda Therapeutics.: Geographical Revenue

Figure 52 Exelixis, Inc.: Key Financials

Figure 53 Exelixis, Inc.: Segmental Revenue

Figure 54 Exelixis, Inc.: Geographical Revenue

Figure 55 Ipsen Pharma: Key Financials

Figure 56 Ipsen Pharma: Segmental Revenue

Figure 57 Ipsen Pharma: Geographical Revenue